SRPTStock Latest News The FlyLeerink remains bullish on Sarepta, views EMBARK study results favorably 2d ago SRPT The Fly Sarepta announces topline results from EMBARK study 2d ago SRPT The Fly Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan ...
Sarepta Therapeutics Q4 Profit Increases, But Misses Estimates 4 days ago • RTTNews Markets Sarepta Therapeutics Q4 24 Earnings Conference Call At 4:30 PM ET 4 days ago • RTTNews Stocks Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now...
Sarepta Therapeutics Q4 Profit Increases, But Misses Estimates 4 days ago • RTTNews Markets Sarepta Therapeutics Q4 24 Earnings Conference Call At 4:30 PM ET 4 days ago • RTTNews Stocks Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now...
94.31亿总市值41.53市盈率TTM 100.000最高价97.060最低价87.42万股成交量99.000今开98.370昨收8558.53万成交额0.94%换手率41.53市盈率(静)9703.21万总股本173.25052周最高6.17市净率90.02亿流通值97.06052周最低--股息TTM9262.11万流通股181.830历史最高--股息率TTM2.99%振幅2.598历史最低97.905平均价1股每手 ...
98.34亿总市值43.31市盈率TTM 103.317最高价97.350最低价92.54万股成交量97.350今开97.190昨收9329.22万成交额1.00%换手率43.31市盈率(静)9703.21万总股本173.25052周最高6.44市净率93.80亿流通值97.06052周最低--股息TTM9254.84万流通股181.830历史最高--股息率TTM6.14%振幅2.598历史最低100.810平均价1股每手 ...
Spreads Protection Strategies Straddles & Strangles Horizontal Spreads Butterfly Spreads Condor Strategies company News & Headlines Key Statistics SEC Filings Competitors Stock Comparison Insider Trades analysts Earnings Estimates Analyst Ratings financials Financial Summary Income Statement Balance Sheet Cash Flow...
Spreads Protection Strategies Straddles & Strangles Horizontal Spreads Butterfly Spreads Condor Strategies company News & Headlines Key Statistics SEC Filings Competitors Stock Comparison Insider Trades analysts Earnings Estimates Analyst Ratings financials Financial Summary Income Statement Balance Sheet Cash Flow...
消息面上,美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症,将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。FDA对可行走的患者授予了传统批准,对于不可行走的患者则授予加速批准。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。
In a report issued on December 19, Bernstein also maintained a Buy rating on the stock with a $1100.00 price target. See today’s best-performing stocks on TipRanks >> Kymera Therapeutics (KYMR) In a report released today, Kelly Shi from Jefferies ...
News Transcripts & Insights SEC Filings Press Releases Related Analysis SRPT Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -19.66% Sarepta Therapeutics, Inc. price and volume Combination chart with 2 data series. Chart represents Sarepta Therapeutics, Inc. price and volume over...